{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:40:30Z","timestamp":1756359630813,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"2","funder":[{"name":"the National Hospital Organization\u2019s fiduciary funds","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Patients on dialysis have limited treatment options for advanced lung cancer because some chemotherapeutic agents are unavailable due to renal dysfunction. A man in his 70s on peritoneal dialysis presented with persistent fever refractory to antibiotics for 2\u2009weeks. Subsequent whole-body CT showed a 5\u2009cm diameter mass in the right lower lobe of the lung with right-sided pleural effusion and osteolytic metastasis of the right iliac bone. The patient was diagnosed with squamous cell carcinoma (cT3N2M1b, stage IVB) harbouring the p.Gly719Ala point mutation on exon 18 of the epidermal growth factor receptor. The patient developed severe respiratory failure due to malignant lymphangitis after a bronchoscopy. He received 30\u2009mg\/day of afatinib, resulting in tumour shrinkage and recovery from respiratory failure. We advocate for aggressive screening of driver oncogenes in patients with lung cancer on dialysis, including those with squamous cell lung cancer.<\/jats:p>","DOI":"10.1136\/bcr-2022-253308","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T22:40:11Z","timestamp":1708468811000},"page":"e253308","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Afatinib treatment of severe respiratory failure due to malignant lymphangitis in a dialysis patient with squamous cell carcinoma of the lung"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-3317","authenticated-orcid":false,"given":"Osamu","family":"Kanai","sequence":"first","affiliation":[{"name":"Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Nephrology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Mio","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2025082722103138000_17.2.e253308.1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"2025082722103138000_17.2.e253308.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"2025082722103138000_17.2.e253308.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1046"},{"key":"2025082722103138000_17.2.e253308.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"2025082722103138000_17.2.e253308.5","doi-asserted-by":"crossref","DOI":"10.2217\/lmt-2021-0001","article-title":"Exceptional response to Afatinib in a patient with persistent G719A EGFR-mutant NSCLC","volume":"11","author":"Kulkarni","year":"2022","journal-title":"Lung Cancer Manag"},{"key":"2025082722103138000_17.2.e253308.6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13318-016-0359-9","article-title":"Influence of renal impairment on the pharmacokinetics of Afatinib: an open-label, single-dose study","volume":"42","author":"Wiebe","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2025082722103138000_17.2.e253308.7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ctrc.2015.09.006","article-title":"Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR Mutation G719A undergoing Hemodialysis","volume":"4","author":"Yamaguchi","year":"2015","journal-title":"Cancer Treatment Communications"},{"key":"2025082722103138000_17.2.e253308.8","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7660806","article-title":"Low serum albumin is associated with poor prognosis in patients receiving peritoneal dialysis treatment","volume":"2022","author":"Shi","year":"2022","journal-title":"J Healthc Eng"},{"key":"2025082722103138000_17.2.e253308.9","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2011.47.1.43"},{"key":"2025082722103138000_17.2.e253308.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08587-w","article-title":"Feasibility and effectiveness of Afatinib for poor performance status patients with EGFR-Mutation-positive non-small-cell lung cancer: a retrospective cohort study","volume":"21","author":"Wu","year":"2021","journal-title":"BMC Cancer"},{"key":"2025082722103138000_17.2.e253308.11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1015"},{"key":"2025082722103138000_17.2.e253308.12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cllc.2018.08.020","article-title":"Targeted tissue and cell-free tumor DNA sequencing of advanced lung squamous-cell carcinoma reveals clinically significant prevalence of actionable alterations","volume":"20","author":"Lam","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2025082722103138000_17.2.e253308.13","first-page":"803","article-title":"EGFR Mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?","volume":"19","author":"Gutierrez","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025082722103138000_17.2.e253308.14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2020.02.023","article-title":"First-line Pembrolizumab in advanced non\u2013small cell lung cancer patients with poor performance status","volume":"130","author":"Facchinetti","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025082722103138000_17.2.e253308.15","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57111273","article-title":"Clinical effectiveness of immune Checkpoint inhibitors in non-small-cell lung cancer with a poor performance status","volume":"57","author":"Kaira","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2025082722103138000_17.2.e253308.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.027"},{"key":"2025082722103138000_17.2.e253308.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3133"},{"key":"2025082722103138000_17.2.e253308.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741"},{"key":"2025082722103138000_17.2.e253308.19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz077"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-253308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:10:38Z","timestamp":1756357838000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-253308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,20]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bcr-2022-253308"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-253308","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}